Header cover image

Hong Kong (HSI) Biotech Industry Analysis

UpdatedJan 29, 2023
DataAggregated Company Financials
Companies39
  • 7D3.4%
  • 3M50.3%
  • 1Y14.3%
  • YTD10.4%

The Biotech industry is up 3.4% in the last week, with Innovent Biologics up 9.0%. This means that the industry has gained 14% over the past year. As for the next few years, earnings are expected to grow by 46% per annum.

Industry Valuation and Performance

Has the Hong Kong Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 29 Jan 2023HK$467.1bHK$34.9b-HK$35,242,741,407.0031.3x-13.3x13.4x
Tue, 27 Dec 2022HK$388.0bHK$33.7b-HK$33,948,658,471.0023.1x-11.4x11.5x
Thu, 24 Nov 2022HK$352.3bHK$33.1b-HK$33,281,981,877.0021.2x-10.6x10.7x
Sat, 22 Oct 2022HK$324.5bHK$33.7b-HK$32,118,113,104.0016.6x-10.1x9.6x
Mon, 19 Sep 2022HK$315.6bHK$34.2b-HK$33,501,064,041.0020.7x-9.4x9.2x
Wed, 17 Aug 2022HK$335.0bHK$32.8b-HK$46,025,407,450.0012.1x-7.3x10.2x
Fri, 15 Jul 2022HK$365.0bHK$33.0b-HK$46,533,006,363.0014x-7.8x11.1x
Sun, 12 Jun 2022HK$357.2bHK$33.0b-HK$46,592,039,317.0014.7x-7.7x10.8x
Tue, 10 May 2022HK$314.0bHK$34.2b-HK$45,397,203,424.0012.8x-6.9x9.2x
Thu, 07 Apr 2022HK$372.3bHK$36.4b-HK$46,242,884,784.0014.7x-8.1x10.2x
Sat, 05 Mar 2022HK$326.8bHK$34.0b-HK$31,239,577,575.0013.7x-10.5x9.6x
Mon, 31 Jan 2022HK$293.1bHK$31.1b-HK$31,841,442,755.0011.3x-9.2x9.4x
Wed, 29 Dec 2021HK$379.2bHK$31.1b-HK$31,826,765,471.0013.2x-11.9x12.2x
Fri, 26 Nov 2021HK$516.9bHK$31.0b-HK$31,721,285,866.0013.7x-16.3x16.7x
Sun, 24 Oct 2021HK$492.3bHK$30.7b-HK$31,774,543,189.0015.3x-15.5x16x
Tue, 21 Sep 2021HK$521.3bHK$30.4b-HK$31,436,180,691.0016.5x-16.6x17.1x
Thu, 19 Aug 2021HK$514.0bHK$30.2b-HK$32,058,827,347.3515.1x-16x17x
Thu, 03 Jun 2021HK$629.6bHK$27.8b-HK$26,637,487,691.0921.6x-23.6x22.7x
Sun, 07 Mar 2021HK$546.6bHK$24.0b-HK$26,645,675,939.7566.8x-20.5x22.7x
Wed, 09 Dec 2020HK$351.8bHK$20.1b-HK$13,901,301,810.9743.2x-25.3x17.5x
Tue, 01 Sep 2020HK$337.6bHK$17.2b-HK$11,180,934,453.5952x-30.2x19.7x
Fri, 05 Jun 2020HK$249.8bHK$16.9b-HK$10,409,928,242.8730.4x-24x14.7x
Mon, 09 Mar 2020HK$184.8bHK$17.1b-HK$7,752,252,997.1835.8x-23.8x10.8x
Price to Earnings Ratio

-22.8x


Total Market Cap: HK$176.6bTotal Earnings: -HK$7,752,252,997.18Total Revenue: HK$17.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Biotech Industry Price to Earnings3Y Average -17.5x202120222023
Current Industry PE
  • Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 14.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 27% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?

HK Market2.72%
Healthcare1.88%
Biotech3.43%
Biotech3.43%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
1801 Innovent BiologicsHK$47.009.0%
+HK$6.0b
52.8%PS13.7x
9926 AkesoHK$51.006.7%
+HK$2.7b
151.9%PS142.9x
9995 RemeGenHK$68.904.3%
+HK$1.5b
43.2%PE116.5x
1952 Everest MedicinesHK$27.6018.5%
+HK$1.3b
8.9%PS6735.5x
2162 Keymed BiosciencesHK$69.905.9%
+HK$1.1b
177.4%PS80.6x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

9969

HK$14.32

InnoCare Pharma

7D

3.5%

1Y

29.2%

1952

HK$27.60

Everest Medicines

7D

18.5%

1Y

8.9%

1801

HK$47.00

Innovent Biologics

7D

9.0%

1Y

52.8%

2616

HK$4.72

CStone Pharmaceuticals

7D

-1.3%

1Y

-18.9%

1875

HK$2.38

TOT BIOPHARM International

7D

-1.2%

1Y

-34.3%

1877

HK$41.60

Shanghai Junshi Biosciences

7D

-3.4%

1Y

-3.0%

2162

HK$69.90

Keymed Biosciences

7D

5.9%

1Y

177.4%

9926

HK$51.00

Akeso

7D

6.7%

1Y

151.9%

6955

HK$15.48

Shandong Boan Biotechnology

7D

-3.0%

1Y

n/a

1167

HK$5.67

Jacobio Pharmaceuticals Group

7D

-2.6%

1Y

-38.1%

2257

HK$50.30

Sirnaomics

7D

-9.6%

1Y

-31.6%

9995

HK$68.90

RemeGen

7D

4.3%

1Y

43.2%

1244

HK$57.45

3D Medicines

7D

6.4%

1Y

n/a

2179

HK$26.60

Jiangsu Recbio Technology

7D

7.5%

1Y

n/a

2157

HK$6.96

Lepu Biopharma

7D

-0.3%

1Y

n/a

2256

HK$2.96

Abbisko Cayman

7D

-3.3%

1Y

-62.0%